As the World Health Assembly (WHA) approaches in late May, WHO members will discuss a proposed resolution on transparency. The U.S. Congress is also considering a number bills that would require greater transparency, and groups like KEI have asked the… Continue Reading →
University of Oklahoma request for U.S. Manufacturing Waiver for rHA, on the grounds that labor costs would be cheaper in China, and in subject revisions, also in Bulgaria. r_Part1_p0012-21.pdf r_r_r_1524003-01-0013_FOIA_Pratt.pdf r_r_r_UniversityofOklahomaEIR1524003-01-0018-p0009-p0052-3ms.pdf r_r_UniversityofOklahomaEIR1524003-01-0014Part1-p0002-p0010.pdf r_r_UniversityofOklahomaEIR1524003-01-0018-p0001-p0007.pdf r_r_US-Manufacturing-Waiver-1524003-01-0013-4-8-10.pdf 2011, May 5. HHS Approval of… Continue Reading →
116th Congress Senate S.102 – Prescription Drug Price Relief Act of 2019 S.366 – FLAT Prices Act S.378 – Stop Price Gouging Act S.474 – Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019 S.476 – Creating… Continue Reading →
Selected cases where infringement exists, but a federal judge permits ongoing infringement. 2006. June 14: z4 Techs., Inc. v. Microsoft Corp., 434 F. Supp. 2d 437, 439 (E.D. Tex. 2006) Patents 6,044,471 and 6,785,825 disclose methods for limiting the unauthorized… Continue Reading →
On April 19, 2019, HealthGap, Knowledge Ecology International, Public Citizen, Social Security Works and the Union for Affordable Cancer Treatment filed comments on a proposed license on National Cancer Institute patented inventions to Senti Bio, for a next generation CAR… Continue Reading →
In an order dated April 11, 2019, Judge Peter J. Messitte granted the NIH’s motion to dismiss for lack of jurisdiction in the lawsuit filed by KEI, which appealed an NIH decision to grant an exclusive license on a CAR… Continue Reading →
This timeline provides copies of official documents not published before about the U.S. pressures in the Dominican Republic during the congressional debates that led to the adoption of the TRIPS-implementing legislation Law 20-00. These documents were obtained via FOIA requests.… Continue Reading →
HOUSE REPORT NO. 96-1307 (Part II), SEPT. 23, 1980 Additional views of Honorable Jack Brooks The major problem I have with H.R. 6933 is that it violates a basic provision of the unwritten contract between the citizens of this country… Continue Reading →
PhRMA’s Special 301 submissions are part of a yearly ritual to shape the “Special 301” Report, an annual review of the global state of intellectual property rights (IPR) protection and enforcement, conducted by the Office of the United States Trade… Continue Reading →
(UPDATE: The NIH provided a response to our comments on February 26, 2019) On February 22, 2019, KEI submitted comments to the Federal Register notice 84 FR 2555 on the “Prospective Grant of an Exclusive Patent License: Virus-Like Particles Vaccines… Continue Reading →